Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW. Soria JC, et al. Among authors: tolcher aw. Eur J Cancer. 2013 May;49(8):1799-807. doi: 10.1016/j.ejca.2013.01.003. Epub 2013 Feb 26. Eur J Cancer. 2013. PMID: 23485230 Clinical Trial.
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC. Macaulay VM, et al. Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26. Ann Oncol. 2013. PMID: 23104723 Free PMC article. Clinical Trial.
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Infante JR, Papadopoulos KP, Bendell JC, Patnaik A, Burris HA 3rd, Rasco D, Jones SF, Smith L, Cox DS, Durante M, Bellew KM, Park JJ, Le NT, Tolcher AW. Infante JR, et al. Among authors: tolcher aw. Eur J Cancer. 2013 Jun;49(9):2077-85. doi: 10.1016/j.ejca.2013.03.020. Epub 2013 Apr 11. Eur J Cancer. 2013. PMID: 23583440 Clinical Trial.
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Tolcher AW, et al. J Clin Oncol. 2009 Dec 1;27(34):5800-7. doi: 10.1200/JCO.2009.23.6745. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786654 Clinical Trial.
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD, Ashton EA, Cooney MM, Sarantopoulos J, Brell JM, Feldman MA, Ruby KE, Matsuda K, Munsey MS, Medina G, Zambito A, Tolcher AW, Remick SC. Ricart AD, et al. Among authors: tolcher aw. Cancer Chemother Pharmacol. 2011 Oct;68(4):959-70. doi: 10.1007/s00280-011-1565-4. Epub 2011 Feb 9. Cancer Chemother Pharmacol. 2011. PMID: 21305290 Clinical Trial.
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A, Braghetti A, Bahleda R, Cohen P, Hospitel M, Veyrat-Follet C, Soria JC. Sessa C, et al. Clin Cancer Res. 2013 Sep 1;19(17):4832-42. doi: 10.1158/1078-0432.CCR-13-0427. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833302 Clinical Trial.
206 results